Remegen

Developer of therapies for the treatment of cancer, autoimmune and eye diseases

placeYantai, Shandong, China calendar_todayFounded 2008 groups3,591 employees language remegen.com

Innovation

69 patent families (34 granted) — focus: Human necessities, Chemistry & metallurgy, Physics & computing, Emerging technologies; filing pace accelerating. Cited 1,596 times.

YearFilings
20152
20164
20172
20183
201910
202012
202113
202220
202320
202434
202534
202615

Investor mix

12 investors on record; lead investors include Lilly Asia Ventures.

Investor typeCountShare
Venture capital217%
Private equity867%
Other / undisclosed217%
Coming soon